Amneal Pharmaceuticals, Inc.AMRXNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +18.40% | +5.50% | +3.24% | +11.68% | +11.47% |
| Gross Profit Growth | +16.58% | +7.49% | +14.53% | +1.64% | +13.05% |
| EBITDA Growth | +240.62% | +238.19% | +24.86% | -20.18% | +42.88% |
| Operating Income Growth | +434.02% | +0.00% | +16.66% | -100.13% | +51.07% |
| Net Income Growth | +0.00% | +0.00% | +273.99% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +268.04% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +269.68% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +27.14% | +1.83% | +1.50% | +1.46% | +1.14% |
| Weighted Average Shares Diluted Growth | +27.14% | +5.43% | +1.07% | +4.88% | +4.83% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -13.06% | +0.00% | +111.36% | -16.45% | +10.36% |
| Free Cash Flow Growth | -8.76% | +0.00% | +97.97% | -14.59% | -8.28% |
| Receivables Growth | +20.15% | +13.67% | +5.71% | +17.54% | +21.16% |
| Inventory Growth | +5.34% | +5.39% | +5.79% | +3.04% | -1.00% |
| Asset Growth | +0.83% | -2.64% | -2.48% | +4.01% | +5.05% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | -5.72% | -6.06% | -5.26% | +1.55% | +5.53% |
| R&D Expense Growth | +20.52% | +6.38% | +34.73% | +3.69% | -37.95% |
| SG&A Expenses Growth | +18.06% | +5.06% | +6.70% | +16.11% | +13.81% |